NasdaqGS:DCOM
NasdaqGS:DCOMBanks

Dime Community Bancshares (DCOM): Is the Stock Currently Undervalued?

Dime Community Bancshares (DCOM) has been on the radar for some investors recently, especially as questions mount around its recent share price trends and fundamentals. There is an interesting combination of market performance and earnings to consider. See our latest analysis for Dime Community Bancshares. Dime Community Bancshares has seen some dramatic swings lately, with a 4.45% jump in its latest session but a year-to-date share price return of -10.19%. Over the past year, the total...
NYSE:V
NYSE:VDiversified Financial

What Visa (V)'s Deeper POS Integration with Mad Mobile Means for Shareholders

Earlier this month, Mad Mobile announced the launch of its Premier Acquirer Services platform in collaboration with Visa's Cybersource, SouthState Bank, and RS2, introducing direct-to-brand payment processing that streamlines payment acceptance and transparency for restaurants and retailers. This collaboration signals a major shift in the restaurant and retail technology industry by integrating acquiring-level control within POS solutions, leveraging Visa's capabilities to simplify payments...
NYSE:ABBV
NYSE:ABBVBiotechs

FDA Approval of EPKINLY Combo Might Change the Case for Investing in AbbVie (ABBV)

In November 2025, AbbVie received full FDA approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for the treatment of relapsed or refractory follicular lymphoma in adults, based on pivotal Phase 3 data showing significant improvement over the standard of care. This regulatory milestone not only converts EPKINLY's earlier accelerated approval to full approval but also marks a meaningful expansion of AbbVie's oncology portfolio in an area of unmet need. We'll...
NasdaqCM:MDXG
NasdaqCM:MDXGBiotechs

MiMedx Group (MDXG) Is Down 8.4% After Strong CAMPAIGN Trial Results for EPIEFFECT Product – What's Changed

MiMedx Group, Inc. recently announced interim results from its CAMPAIGN trial, showing its EPIEFFECT product outperformed standard care for nonhealing diabetic foot ulcers, with findings published in a peer-reviewed journal and expanded data presented at a major research summit. A key insight is that advanced predictive modeling from the ongoing trial demonstrated a 98.5% probability of EPIEFFECT’s superiority, potentially elevating its profile in the advanced wound care market. We’ll...
NYSE:VAC
NYSE:VACHospitality

Marriott Vacations Worldwide (VAC): Assessing Value After Recent 30% Share Price Decline

Marriott Vacations Worldwide (VAC) shares have been trending lower over the month, with returns down nearly 30%. This activity has sparked conversations among investors who are curious about the company’s fundamentals and long-term prospects. See our latest analysis for Marriott Vacations Worldwide. The latest swing capped off a sharp 30-day share price return of -29.33%, following a challenging period for Marriott Vacations Worldwide. While this month’s movement stands out, the real story is...
NasdaqGS:DLO
NasdaqGS:DLODiversified Financial

A Fresh Look at DLocal (NasdaqGS:DLO) Valuation Following Strong Q3 Earnings Growth

DLocal (NasdaqGS:DLO) released its third quarter results, posting much higher sales and net income compared to the same period last year. This jump highlights continued growth and operational efficiency for the company, which has caught investor attention. See our latest analysis for DLocal. DLocal’s upbeat earnings have come at a time when the stock’s momentum has been notably mixed. While the 1-year total shareholder return sits at an impressive 20.92%, recent 30-day and 90-day share price...
NYSE:KVYO
NYSE:KVYOSoftware

Are Expanding Partnerships Enough to Support Klaviyo’s Value After a 33.6% Drop?

Ever wondered whether Klaviyo is a bargain at current prices, or if there is more risk than reward hiding in the numbers? If you are eyeing this stock’s place in your portfolio, you are definitely not alone. The share price has seen ups and downs lately. It slipped 3.4% this past week but gained 5.0% over the last month. These movements make investors wonder if the tides are turning or if rougher waters lie ahead after a 33.6% drop year-to-date. Recent news has highlighted Klaviyo’s...
NYSE:T
NYSE:TTelecom

Does AT&T's Rapid 5G Mid-Band Expansion Change the Bull Case for AT&T (T)?

Earlier this week, AT&T announced the rapid nationwide deployment of mid-band spectrum acquired from EchoStar, upgrading nearly 23,000 cell sites to deliver up to 80% faster 5G download speeds and expanded connectivity for mobility and home internet customers in over 5,300 cities across 48 states. This large-scale integration enhances AT&T's network leadership and positions the company for capital-efficient long-term growth by increasing its ability to acquire and retain customers who...
NasdaqGS:HON
NasdaqGS:HONIndustrials

Honeywell (HON): A Fresh Look at Valuation Following Bank of America Downgrade and Solstice Advanced Materials Spinoff

Honeywell International (HON) shares are catching attention after Bank of America downgraded the stock to sell. The move was attributed to expectations of slower earnings growth in 2026 and the spinoff of Solstice Advanced Materials. See our latest analysis for Honeywell International. Honeywell’s share price has taken a noticeable hit recently, with a 30-day decline of 8% that extends to a sharp 15.7% fall year-to-date. Even factoring in dividends, total shareholder return sits at -10% over...
NasdaqGS:HSAI
NasdaqGS:HSAIAuto Components

Hesai Group (NasdaqGS:HSAI): Valuation Insights Following Profit Surge, Upgraded Outlook, and New Li Auto Deal

Hesai Group (NasdaqGS:HSAI) just raised its full-year earnings guidance and posted third-quarter results that highlight a sharp swing to profitability. At the same time, the company landed a new exclusive lidar supply deal with Li Auto. See our latest analysis for Hesai Group. Fresh off new exclusivity with Li Auto and upwardly revised earnings guidance, Hesai Group’s stock continues to trade with significant volatility. While the share price dipped roughly 29% over the last month, its...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

Did Positive Aficamten Trial Results Just Shift Cytokinetics' (CYTK) Investment Narrative?

In recent days, Cytokinetics announced additional positive clinical trial data for aficamten in hypertrophic cardiomyopathy, with results showing significant improvements across key clinical and patient-reported measures compared to metoprolol. These findings, presented at major cardiology conferences and published in a leading medical journal, further differentiate aficamten as a promising therapy in the cardiomyopathy space. Alongside new data, recent announcements reflect growing...
NasdaqGS:SEIC
NasdaqGS:SEICCapital Markets

SEI Investments (SEIC): Exploring Valuation Following Recent Share Price Decline

SEI Investments (SEIC) has been on investors' radar lately, trading at around $80.04 per share. With shares down 11% over the past 3 months, some are eyeing the current valuation for potential opportunities or risks. See our latest analysis for SEI Investments. After a drop over the last quarter, SEI Investments is still holding on to a 0.2% total shareholder return for the past year and a solid 53.8% five-year total return. The recent share price slide suggests fading momentum but does not...
NYSE:OII
NYSE:OIIEnergy Services

Oceaneering International (OII): Assessing Valuation as Shares Tick Higher Despite Mixed Long-Term Returns

Oceaneering International (OII) has seen its stock move a bit recently, gaining around 3% in the past day even as its returns over the month and past year remain mixed. Investors are now weighing its current price of $24.15 in light of recent performance. See our latest analysis for Oceaneering International. Momentum has been a bit uneven for Oceaneering International, with yesterday’s 3% share price uptick offering a spark after a stretch of mixed action. While the 1-year total shareholder...
NasdaqGS:AUR
NasdaqGS:AURSoftware

Is Rising Short Interest a Test of Aurora Innovation’s (AUR) Long-Term Vision?

Recently, Aurora Innovation Inc's short interest as a percent of float rose by 11.56%, with 14.28% of all regular shares now sold short, surpassing the average of its peer group. This shift indicates a significant increase in bearish sentiment among investors, pointing to heightened scrutiny and debate over the company's prospects. With short interest notably higher than peers, we’ll explore how rising bearish sentiment shapes Aurora Innovation’s investment narrative. This technology could...
NasdaqGS:CSWC
NasdaqGS:CSWCCapital Markets

How Investors Are Reacting To Capital Southwest (CSWC) Approving New Monthly and Supplemental Dividends for 2026

Capital Southwest Corporation’s Board of Directors has declared monthly dividends of US$0.1934 per share payable in January, February, and March 2026, alongside a supplemental quarterly dividend of US$0.06 per share in March 2026; the dividends will be available to shareholders of record as of the corresponding ex-dates each month. The company’s dividend reinvestment plan and these regular distributions reinforce its focus on providing shareholder returns, even as recent earnings results...
NYSE:CXM
NYSE:CXMSoftware

How Will Sprinklr's (CXM) Enhanced Partnership With SAMY Influence Client Outcomes and Brand Strategy?

Sprinklr recently announced an expanded global partnership with SAMY, aiming to integrate its Unified-CXM platform with SAMY’s social-first marketing expertise to create end-to-end solutions for brands. A standout aspect of this collaboration is its immediate impact, exemplified by the development of Diageo’s Foresight System, which uses social data to turn emerging cultural trends into actionable business insights. To assess how this enhanced alliance with SAMY shapes Sprinklr’s investment...
NYSE:TFC
NYSE:TFCBanks

How Investors Are Reacting To Truist Financial (TFC) Hiring Microsoft Veteran as Chief AI and Data Officer

Truist Financial Corporation recently appointed Pascal Belaud, a longtime Microsoft executive, as chief AI & data officer to lead its AI, data, and automation initiatives across the enterprise starting November 24, 2025. This significant hire reflects Truist’s growing commitment to digital transformation, signaling a push to leverage artificial intelligence and automation for company-wide innovation. We’ll now explore how Belaud’s appointment as chief AI & data officer could influence Truist...
NasdaqGS:PGNY
NasdaqGS:PGNYHealthcare

Progyny (PGNY) Is Up 5.3% After Strong Results, Share Buyback, and Major Insider Buying—What's Changed

Progyny recently reported a 9% year-over-year revenue increase for its third quarter, raised its full-year guidance, announced a US$200 million share repurchase program, and disclosed a major insider purchase by CEO Peter Anevski of 79,500 shares worth US$1.93 million. New research also highlighted untapped opportunities in men's fertility support, while the company's robust results point to rising demand and continued business expansion in the fertility benefits space. We'll explore how...
NYSE:LUV
NYSE:LUVAirlines

Does Southwest Airlines' (LUV) Dividend Reveal Strength in Its Capital Allocation Strategy?

Southwest Airlines' Board of Directors has declared a quarterly cash dividend of US$0.18 per share for shareholders of record as of December 26, 2025, with payment scheduled for January 16, 2026. This dividend declaration indicates the company's continued commitment to returning value to shareholders and may reflect underlying confidence in its financial position and outlook. We'll examine how Southwest Airlines' latest dividend declaration could influence its investment narrative,...
NasdaqGS:CRNX
NasdaqGS:CRNXPharmaceuticals

Will the CAREFNDR Phase 3 Launch Broaden Crinetics Pharmaceuticals' (CRNX) Long-Term Growth Narrative?

Crinetics Pharmaceuticals recently announced that the first patient has been randomized in its pivotal Phase 3 CAREFNDR trial, a global study evaluating once-daily, oral paltusotine for carcinoid syndrome due to well-differentiated neuroendocrine tumors. This marks a significant step as paltusotine, already approved in the U.S. for acromegaly, could see its clinical application broadened to another rare disease area if successful. We'll explore what the launch of this Phase 3 trial could...
NYSE:CB
NYSE:CBInsurance

Will Chubb's (CB) AI Investment Sharpen Its Edge in Digital Insurance and Stakeholder Engagement?

Earlier this month, Chubb introduced an AI-powered optimization engine in its Chubb Studio platform at the Singapore Fintech Festival, announced executive appointments including Bill Hazelton as COO for North America Field Operations and Susan Spivak as Senior Vice President of Investor Relations, and declared a quarterly dividend of US$0.97 per share payable on January 2, 2026. The launch of Chubb Studio's AI optimization engine signals a move toward greater personalization and digital...
NasdaqGS:JD
NasdaqGS:JDMultiline Retail

How Investors May Respond To JD (JD) Repurchasing Shares and Entering China's Local Services Market

Earlier this month, JD.com completed the repurchase of 80,900,000 shares, approximately 5.57% of its shares outstanding, for US$1.5 billion and officially launched its "JD Review" platform alongside a new food delivery app, marking its entry into China's local services market with AI-driven recommendations and integrated ordering. The move signals JD.com's commitment to integrating e-commerce with local services and leveraging technology to compete in a market historically dominated by other...
NYSE:WKC
NYSE:WKCOil and Gas

Expanded $2 Billion Credit Facility Could Be a Game Changer for World Kinect (WKC)

Earlier this month, World Kinect announced it amended and extended its senior unsecured credit facility to US$2 billion, increasing revolving commitments, replacing a portion of its term loan, and securing a new maturity date in November 2030 with an additional extension option. The revised agreement lowers borrowing costs, expands operating flexibility, and supports World Kinect’s capital allocation goals and future growth plans. We’ll now explore how this amended credit facility, with its...
NasdaqGS:POWL
NasdaqGS:POWLElectrical

Will AI-Driven Utility Growth Offset Powell Industries’ (POWL) Slower Order Intake Over Time?

Powell Industries recently reported its fourth quarter and full-year earnings for Fiscal 2025, with quarterly sales of US$297.98 million and net income of US$51.42 million, both higher than the prior year. An interesting detail is that the company’s Electric Utility segment, supported by increasing AI data center investments, grew significantly over the past year, balancing a drop in quarterly order intake. We’ll explore how robust Electric Utility growth, despite declining new orders, could...